Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JANX NASDAQ:LNTH NASDAQ:NUVL NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$26.40-4.9%$24.62$22.48▼$71.71$1.64B2.86876,731 shs908,736 shsLNTHLantheus$70.18-4.6%$78.80$69.12▼$118.71$5.09B0.12980,999 shs1.35 million shsNUVLNuvalent$83.40-2.7%$77.21$55.54▼$113.51$6.15B1.31506,626 shs334,196 shsTGTXTG Therapeutics$37.91-3.3%$36.41$16.65▼$46.48$6.22B1.912.85 million shs1.79 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics-4.86%+4.97%+16.20%-11.08%-39.88%LNTHLantheus-4.65%-13.69%-11.15%-30.73%-42.29%NUVLNuvalent-2.67%+3.05%+10.42%+16.42%+3.60%TGTXTG Therapeutics-3.27%+2.24%+7.79%-1.07%+71.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJANXJanux Therapeutics2.0579 of 5 stars3.51.00.00.02.42.50.0LNTHLantheus4.6109 of 5 stars3.42.00.04.23.32.51.9NUVLNuvalent3.3328 of 5 stars4.61.00.00.02.93.30.0TGTXTG Therapeutics3.6807 of 5 stars2.40.00.03.52.92.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJANXJanux Therapeutics 3.08Buy$91.89248.06% UpsideLNTHLantheus 2.83Moderate Buy$131.2086.95% UpsideNUVLNuvalent 3.17Buy$119.6043.41% UpsideTGTXTG Therapeutics 2.80Moderate Buy$43.8015.54% UpsideCurrent Analyst Ratings BreakdownLatest JANX, TGTX, NUVL, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform7/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.007/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.006/30/2025NUVLNuvalentThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/25/2025NUVLNuvalentRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$105.00 ➝ $112.006/24/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$115.006/24/2025NUVLNuvalentLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $140.006/24/2025NUVLNuvalentHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $130.006/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJANXJanux Therapeutics$10.59M147.51N/AN/A$19.49 per share1.35LNTHLantheus$1.53B3.17$6.76 per share10.38$15.65 per share4.48NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ATGTXTG Therapeutics$386.39M15.58$0.12 per share326.68$1.43 per share26.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)LNTHLantheus$312.44M$3.5219.9411.12N/A16.55%36.99%20.55%7/30/2025 (Estimated)NUVLNuvalent-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24157.9637.91N/A10.13%18.88%7.05%8/5/2025 (Estimated)Latest JANX, TGTX, NUVL, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NUVLNuvalent-$1.27N/AN/AN/AN/AN/A8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/5/2025Q2 2025TGTXTG Therapeutics$0.27N/AN/AN/A$147.76 millionN/A7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJANXJanux TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJANXJanux TherapeuticsN/A58.4758.47LNTHLantheus0.495.745.46NUVLNuvalentN/A14.4814.48TGTXTG Therapeutics1.034.023.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJANXJanux Therapeutics75.39%LNTHLantheus99.06%NUVLNuvalent97.26%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipJANXJanux Therapeutics8.10%LNTHLantheus1.50%NUVLNuvalent10.20%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJANXJanux Therapeutics3059.17 million54.38 millionOptionableLNTHLantheus70069.19 million68.15 millionOptionableNUVLNuvalent4071.81 million64.48 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableJANX, TGTX, NUVL, and LNTH HeadlinesRecent News About These CompaniesTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Hussman Strategic Advisors Inc.July 18 at 10:39 AM | marketbeat.comJackson Creek Investment Advisors LLC Has $1.40 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18 at 10:08 AM | marketbeat.comEdgestream Partners L.P. Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18 at 5:02 AM | marketbeat.comSigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 17 at 5:25 AM | marketbeat.comBank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 15, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at The Goldman Sachs GroupJuly 13, 2025 | americanbankingnews.comTG Therapeutics (TGTX) Gets a Hold from Goldman SachsJuly 12, 2025 | theglobeandmail.comBanque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)July 11, 2025 | marketbeat.comTG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90July 10, 2025 | msn.comTG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite RatingJuly 10, 2025 | msn.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 10, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLCJuly 9, 2025 | marketbeat.comAxsome Therapeutics Sees Relative Strength Rating Climb To 79July 8, 2025 | msn.comPenserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8, 2025 | marketbeat.comNew York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 7, 2025 | marketbeat.comBraun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comJim Cramer on TG Therapeutics: “You Should Buy the Stock”July 2, 2025 | insidermonkey.comKymera Therapeutics Shows Market Leadership With Jump To 93 RS RatingJuly 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJANX, TGTX, NUVL, and LNTH Company DescriptionsJanux Therapeutics NASDAQ:JANX$26.40 -1.35 (-4.86%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$26.40 +0.01 (+0.02%) As of 07/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Lantheus NASDAQ:LNTH$70.18 -3.42 (-4.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$70.92 +0.73 (+1.05%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Nuvalent NASDAQ:NUVL$83.40 -2.29 (-2.67%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$83.38 -0.02 (-0.02%) As of 07/18/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$37.91 -1.28 (-3.27%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$38.16 +0.25 (+0.65%) As of 07/18/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
